Piperacillin with tazobactam
Brand names: Tazocin
An intravenous broad-spectrum antibacterial combining an extended-spectrum penicillin with a beta-lactamase inhibitor, used for serious infections including hospital-acquired pneumonia, intra-abdominal and complicated soft-tissue infections, and sepsis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Piperacillin inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins, while tazobactam irreversibly inhibits many bacterial beta-lactamases, restoring and extending activity against otherwise resistant Gram-negative and anaerobic organisms.
Prescribing in practice
- It contains a penicillin and is contraindicated in patients with a history of severe hypersensitivity to penicillins or other beta-lactams — check allergy status before administration.
- The dose must be reduced in renal impairment, and the significant sodium content should be considered in patients with cardiac failure or sodium restriction.
- Reduced efficacy of combined hormonal contraception is a recognised antibiotic caution, and concurrent use with certain anticoagulants warrants closer monitoring.
Monitoring
Monitor renal function, electrolytes and full blood count during prolonged therapy, as neutropenia and electrolyte disturbance can occur.
Counselling the patient
- This antibiotic is given by drip into a vein in hospital for serious infection.
- Tell the team immediately about any allergy to penicillin or other antibiotics.
- Report any rash, breathing difficulty, or severe or persistent diarrhoea during or after treatment.
Evidence & guidelines
Piperacillin with tazobactam is a widely used empirical agent in UK hospital sepsis and antimicrobial protocols for serious infection.
Reference: NICE NG139/NG143; UKHSA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023